384 related articles for article (PubMed ID: 18519523)
1. Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial.
Sultzer DL; Davis SM; Tariot PN; Dagerman KS; Lebowitz BD; Lyketsos CG; Rosenheck RA; Hsiao JK; Lieberman JA; Schneider LS;
Am J Psychiatry; 2008 Jul; 165(7):844-54. PubMed ID: 18519523
[TBL] [Abstract][Full Text] [Related]
2. Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD.
Vigen CL; Mack WJ; Keefe RS; Sano M; Sultzer DL; Stroup TS; Dagerman KS; Hsiao JK; Lebowitz BD; Lyketsos CG; Tariot PN; Zheng L; Schneider LS
Am J Psychiatry; 2011 Aug; 168(8):831-9. PubMed ID: 21572163
[TBL] [Abstract][Full Text] [Related]
3. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Ballard C; Waite J
Cochrane Database Syst Rev; 2006 Jan; (1):CD003476. PubMed ID: 16437455
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease.
Schneider LS; Tariot PN; Dagerman KS; Davis SM; Hsiao JK; Ismail MS; Lebowitz BD; Lyketsos CG; Ryan JM; Stroup TS; Sultzer DL; Weintraub D; Lieberman JA;
N Engl J Med; 2006 Oct; 355(15):1525-38. PubMed ID: 17035647
[TBL] [Abstract][Full Text] [Related]
5. Management of aggression, agitation, and psychosis in dementia: focus on atypical antipsychotics.
Aupperle P
Am J Alzheimers Dis Other Demen; 2006; 21(2):101-8. PubMed ID: 16634465
[TBL] [Abstract][Full Text] [Related]
6. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
[TBL] [Abstract][Full Text] [Related]
7. Atypical antipsychotics for the treatment of dementia-related behaviors: an update.
Daiello LA
Med Health R I; 2007 Jun; 90(6):191-4. PubMed ID: 17633594
[TBL] [Abstract][Full Text] [Related]
8. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison.
Keefe RS; Sweeney JA; Gu H; Hamer RM; Perkins DO; McEvoy JP; Lieberman JA
Am J Psychiatry; 2007 Jul; 164(7):1061-71. PubMed ID: 17606658
[TBL] [Abstract][Full Text] [Related]
9. Oral risperidone, olanzapine and quetiapine versus haloperidol in psychotic agitation.
Villari V; Rocca P; Fonzo V; Montemagni C; Pandullo P; Bogetto F
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):405-13. PubMed ID: 17900775
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial.
Tariot PN; Schneider L; Katz IR; Mintzer JE; Street J; Copenhaver M; Williams-Hughes C
Am J Geriatr Psychiatry; 2006 Sep; 14(9):767-76. PubMed ID: 16905684
[TBL] [Abstract][Full Text] [Related]
11. A markov model of the cost effectiveness of olanzapine treatment for agitation and psychosis in Alzheimer's disease.
Kirbach S; Simpson K; Nietert PJ; Mintzer J
Clin Drug Investig; 2008; 28(5):291-303. PubMed ID: 18407715
[TBL] [Abstract][Full Text] [Related]
12. Lack of Early Improvement with Antipsychotics is a Marker for Subsequent Nonresponse in Behavioral and Psychological Symptoms of Dementia: Analysis of CATIE-AD Data.
Yoshida K; Roberts R; Suzuki T; Lebowitz B; Reeves S; Howard R; Abe T; Mimura M; Uchida H
Am J Geriatr Psychiatry; 2017 Jul; 25(7):708-716. PubMed ID: 28215900
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics for psychosis in adolescents.
Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
Cochrane Database Syst Rev; 2013 Oct; (10):CD009582. PubMed ID: 24129841
[TBL] [Abstract][Full Text] [Related]
14. Baseline Predictors of Antipsychotic Treatment Continuation and Response at Week 8 in Patients with Alzheimer's Disease with Psychosis or Aggressive Symptoms: An Analysis of the CATIE-AD Study.
Nagata T; Nakajima S; Shinagawa S; Plitman E; Nakayama K; Graff-Guerrero A; Mimura M
J Alzheimers Dis; 2017; 60(1):263-272. PubMed ID: 28800334
[TBL] [Abstract][Full Text] [Related]
15. How effective is it to sequentially switch among Olanzapine, Quetiapine and Risperidone?--A randomized, open-label study of algorithm-based antipsychotic treatment to patients with symptomatic schizophrenia in the real-world clinical setting.
Suzuki T; Uchida H; Watanabe K; Nomura K; Takeuchi H; Tomita M; Tsunoda K; Nio S; Den R; Manki H; Tanabe A; Yagi G; Kashima H
Psychopharmacology (Berl); 2007 Dec; 195(2):285-95. PubMed ID: 17701027
[TBL] [Abstract][Full Text] [Related]
16. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation).
Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE
Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083
[TBL] [Abstract][Full Text] [Related]
17. Effect of second-generation antipsychotics on caregiver burden in Alzheimer's disease.
Mohamed S; Rosenheck R; Lyketsos CG; Kaczynski R; Sultzer DL; Schneider LS
J Clin Psychiatry; 2012 Jan; 73(1):121-8. PubMed ID: 21939611
[TBL] [Abstract][Full Text] [Related]
18. Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia.
Deberdt WG; Dysken MW; Rappaport SA; Feldman PD; Young CA; Hay DP; Lehman DL; Dossenbach M; Degenhardt EK; Breier A
Am J Geriatr Psychiatry; 2005 Aug; 13(8):722-30. PubMed ID: 16085789
[TBL] [Abstract][Full Text] [Related]
19. Comparison of longer-term safety and effectiveness of 4 atypical antipsychotics in patients over age 40: a trial using equipoise-stratified randomization.
Jin H; Shih PA; Golshan S; Mudaliar S; Henry R; Glorioso DK; Arndt S; Kraemer HC; Jeste DV
J Clin Psychiatry; 2013 Jan; 74(1):10-8. PubMed ID: 23218100
[TBL] [Abstract][Full Text] [Related]
20. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Loy JH; Merry SN; Hetrick SE; Stasiak K
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
